Hybrid, High-Dose Dual, and Bismuth Quadruple Therapies for the First-Line Treatment of Helicobacter Pylori Infection in Taiwan
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The American Journal of Gastroenterology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of Helicobacter pylori infection in Taiwan: a multicenter, open-label, randomized trial
Am. J. Gastroenterol 2023 Mar 20;[EPub Ahead of Print], PI Hsu, KY Chen, WC Tai, JC Yang, FW Tsay, YH Liu, CL Chen, CL Lee, HZ Yeh, CH Kuo, SK Chuah, HC Lee, CB Shie, SI Shiu, JY Kao, Y Yamaoka, DY Graham, DC WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.